Our pre-clinical findings demonstrate that the addition of BCL-XL inhibitors to BRAF inhibitor treatment is worthy of clinical investigation as a means of improving outcomes for BRAFV600E CRC patients. This evidence concerns the gene BCL2L1 and colorectal carcinoma.